133 related articles for article (PubMed ID: 16117152)
1. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
Totolian NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
[No Abstract] [Full Text] [Related]
2. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
Deisenhammer F; Giovannoni G
Mult Scler; 2004 Dec; 10(6):713-4; author reply 715. PubMed ID: 15584500
[No Abstract] [Full Text] [Related]
3. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
Milanese C; La Mantia L; Palumbo R; Martinelli V; Murialdo A; Zaffaroni M; Caputo D; Capra R; Bergamaschi R;
J Neurol Neurosurg Psychiatry; 2003 Dec; 74(12):1689-92. PubMed ID: 14638892
[TBL] [Abstract][Full Text] [Related]
4. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
5. Interferon beta in multiple sclerosis: predicting response at an early stage.
Killestein J; Hartung HP
J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):616-7. PubMed ID: 18487553
[No Abstract] [Full Text] [Related]
6. Experiences in treatment of multiple sclerosis with betaferon in federation of Bosnia and Herzegovina.
Mehmedika-Suljic E; Burza-Bosnjak E; Bera M; Hasovic M; Sinanovic O
Med Arh; 2007; 61(1):34-6. PubMed ID: 17582973
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Baum K;
J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
[TBL] [Abstract][Full Text] [Related]
8. [Interferon beta-1b (Betaferon)therapy in patients with relapsing-remitting multiple sclerosis: findings of a prospective, multi-center study of disease progression].
Oentrich W; Dose T; Friedmann D; Haupts M; Haller P; Hartung HP; Walther EU; König N; Schröder G; Stürzebecher CS
Nervenarzt; 2001 Apr; 72(4):286-92. PubMed ID: 11320864
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M; Janghorbani M; Shaygannejad V
Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
Antonetti F; Finocchiaro O; Mascia M; Terlizzese MG; Jaber A
J Interferon Cytokine Res; 2002 Dec; 22(12):1181-4. PubMed ID: 12581490
[TBL] [Abstract][Full Text] [Related]
11. Landmark papers in multiple sclerosis.
Cross AH
Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
[No Abstract] [Full Text] [Related]
12. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Goodin DS
Neurology; 2006 Oct; 67(7):1313-4. PubMed ID: 17030783
[No Abstract] [Full Text] [Related]
13. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
14. [PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].
Limmroth V
Internist (Berl); 2001 Feb; 42(2):305-7. PubMed ID: 11244885
[No Abstract] [Full Text] [Related]
15. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results.
Milanese C; Beghi E; Giordano L; La Mantia L; Mascoli N; Confalonieri P;
Neurol Sci; 2005 Dec; 26 Suppl 4():S171-3. PubMed ID: 16388352
[TBL] [Abstract][Full Text] [Related]
16. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
17. Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
Rudge P
Mult Scler; 2004 Apr; 10(2):123-5. PubMed ID: 15124755
[No Abstract] [Full Text] [Related]
18. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
20. The best clinical paper on multiple sclerosis in 2012: commentary.
Hutchinson M
Mult Scler; 2013 Apr; 19(5):522-3. PubMed ID: 23599183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
